Indian drugmakers look beyond generics as Sun Pharma buys Organon

Nation's largest overseas pharma deal comes as firms aim to boost global presence

India's Sun Pharma is buying U.S.-based Organon for $11.75 billion in what is the largest overseas acquisition by a drugmaker from the South Asian country. © Reuters

BENGALURU -- Indian drugmaker Sun Pharma said on Monday that it will fork out $11.75 billion in cash to buy U.S.-based Organon, underscoring a broader push by pharmaceutical companies in the South Asian nation to diversify beyond low-value generics to cement their footprint in international markets.